Diabetes

Sep 27, 2024

Promising Data from the First Dedicated Kidney Outcomes Trial with GLP-1 Receptor Agonist, Semaglutide, in Patients with Type 2 Diabetes and Chronic Kidney Disease

Sep 27, 2024

Pooled Analysis of Finerenone Presented at EASD 2024, Poised to Strengthen its Position in the Cardio-Kidney-Metabolic Market Further

Sep 12, 2024

SpectraWAVE raised $50M; Rockwell Medical signed dialysis deal; Modular Medical got FDA nod for Modd1 pump; iRhythm’s Zio approved in Japan; Autonomix trial showed 83% pain reduction; Insulin Efsitora Alfa improved A1C.

Jul 23, 2024

CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy 

Jul 16, 2024

Immutep’ First-Line Treatment Positive Outcomes; Pfizer’s Once-Daily Oral GLP-1 Agonist Danuglipron; FDA Issues Complete Response Letter to Novo Nordisk; Arcutis’ ZORYVE® Cream 0.15% FDA Approval; NICE Recommends Ebglyss For Moderate To Severe Atopic Dermatitis

Jun 25, 2024

Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval

Apr 03, 2024

Nutrition Nexus: Illuminating the Growth Trajectory Path in the Dietary Supplements Market

Dec 25, 2023

Future Avenues for Prediabetes Treatment: The Road Ahead

Dec 05, 2023

FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev; Roche and Carmot Therapeutics’s Definitive Merger Agreement; AbbVie to Acquire ImmunoGen; FDA Grants Orphan Drug Designation to LP-284; Merck Announces Commercialization Agreement With Abbisko; Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial

Oct 25, 2023

Charting the Growth of the Insulin Pens Market Amidst Rising Demand

Newsletter/Whitepaper